- Home
- MSB vs MREO Comparison
MSB vs MREO Comparison
Compare MSB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- MREO
- Stock Information
- Founded
- MSB 1961
- MREO 2015
- Country
- MSB United States
- MREO United Kingdom
- Employees
- MSB N/A
- MREO N/A
- Industry
- MSB Metal Mining
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- MREO Health Care
- Exchange
- MSB Nasdaq
- MREO Nasdaq
- Market Cap
- MSB 351.7M
- MREO 369.2M
- IPO Year
- MSB N/A
- MREO N/A
- Fundamental
- Price
- MSB $24.21
- MREO $1.94
- Analyst Decision
- MSB
- MREO Strong Buy
- Analyst Count
- MSB 0
- MREO 7
- Target Price
- MSB N/A
- MREO $7.71
- AVG Volume (30 Days)
- MSB 33.5K
- MREO 1.0M
- Earning Date
- MSB 01-01-0001
- MREO 05-14-2025
- Dividend Yield
- MSB 26.49%
- MREO N/A
- EPS Growth
- MSB 714.88
- MREO N/A
- EPS
- MSB 7.00
- MREO N/A
- Revenue
- MSB $26,785,162.00
- MREO N/A
- Revenue This Year
- MSB N/A
- MREO N/A
- Revenue Next Year
- MSB N/A
- MREO $52.12
- P/E Ratio
- MSB $3.83
- MREO N/A
- Revenue Growth
- MSB 85.21
- MREO N/A
- 52 Week Low
- MSB $15.93
- MREO $2.11
- 52 Week High
- MSB $37.00
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MSB 37.68
- MREO 33.13
- Support Level
- MSB $26.02
- MREO $2.23
- Resistance Level
- MSB $27.77
- MREO $2.37
- Average True Range (ATR)
- MSB 1.24
- MREO 0.16
- MACD
- MSB -0.19
- MREO -0.02
- Stochastic Oscillator
- MSB 1.24
- MREO 2.82
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).